Zobrazeno 1 - 10 of 1 959 pro vyhledávání: '"QUINTINI G"'
1
Akademický článek
A phase 3, randomised, observer-blinded, placebo controlled-trial evaluating the safety and immunogenicity of investigational SARS-CoV-2 mRNA vaccine CVnCoV in adult healthcare workers in Mainz (Germany).
Autor: Kowalzik F; Children's Hospital, University Medical Center of the Johannes Gutenberg-Universität Mainz, Langenbeckstr. 1, D-55131, Mainz, Germany., Teschner D; Department of Hematology, and Medical Oncology, University Medical Center of the Johannes Gutenberg-Universität Mainz, Langenbeckstr. 1, D-55131, Mainz, Germany.; Department of Internal Medicine II, University Hospital Würzburg, Oberdürrbacher Straße 6, D-97080, Würzburg, Germany., Mesquita M; CureVac SE, Tübingen, Germany., Jensen C; Children's Hospital, University Medical Center of the Johannes Gutenberg-Universität Mainz, Langenbeckstr. 1, D-55131, Mainz, Germany., Schreiner D; Children's Hospital, University Medical Center of the Johannes Gutenberg-Universität Mainz, Langenbeckstr. 1, D-55131, Mainz, Germany., Kronfeld K; Interdisciplinary Center for Clinical Trials (IZKS), University Medical Center of the Johannes Gutenberg-Universität Mainz, Langenbeckstr. 1, D-55131, Mainz, Germany., Tubic-Grozdanis M; Pharmacy Department, University Medical Center of the Johannes Gutenberg-Universität Mainz, Langenbeckstr. 1, D-55131, Mainz, Germany., Cheatham-Seitz D; CureVac SE, Tübingen, Germany., Hettich F; CureVac SE, Tübingen, Germany., Quintini G; CureVac SE, Tübingen, Germany., Schoenborn-Kellenberger O; CureVac SE, Tübingen, Germany., Codó P; CureVac SE, Tübingen, Germany., von Eisenhart-Rothe P; CureVac SE, Tübingen, Germany., Mann P; CureVac SE, Tübingen, Germany., Oostvogels L; CureVac SE, Tübingen, Germany., Gehring S; Children's Hospital, University Medical Center of the Johannes Gutenberg-Universität Mainz, Langenbeckstr. 1, D-55131, Mainz, Germany.
Publikováno v: Vaccine: X [Vaccine X] 2024 Jun 20; Vol. 19, pp. 100512. Date of Electronic Publication: 2024 Jun 20 (Print Publication: 2024).
Zobrazit plný text záznamu
2
Akademický článek
Innate Responses to the Former COVID-19 Vaccine Candidate CVnCoV and Their Relation to Reactogenicity and Adaptive Immunogenicity.
Autor: Wolz OO; CureVac SE, 72076 Tübingen, Germany., Vahrenhorst D; CureVac SE, 72076 Tübingen, Germany., Quintini G; CureVac SE, 72076 Tübingen, Germany., Lemberg C; CureVac SE, 72076 Tübingen, Germany., Koch SD; CureVac SE, 72076 Tübingen, Germany., Kays SK; CureVac SE, 72076 Tübingen, Germany., Walz L; CureVac SE, 72076 Tübingen, Germany., Kulkarni N; ImmunoScape Pte Ltd., Singapore 139954, Singapore., Fehlings M; ImmunoScape Pte Ltd., Singapore 139954, Singapore., Wengenmayer P; CureVac SE, 72076 Tübingen, Germany., Heß J; CureVac SE, 72076 Tübingen, Germany., Oostvogels L; CureVac SE, 72076 Tübingen, Germany., Lazzaro S; CureVac SE, 72076 Tübingen, Germany., von Eisenhart-Rothe P; CureVac SE, 72076 Tübingen, Germany., Mann P; CureVac SE, 72076 Tübingen, Germany.
Publikováno v: Vaccines [Vaccines (Basel)] 2024 Apr 06; Vol. 12 (4). Date of Electronic Publication: 2024 Apr 06.
Zobrazit plný text záznamu
3
Corrigendum to "Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study" [Vaccine: X 11 (2022) 100189].
Autor: Sáez-Llorens X; Cevaxin, The Panama Clinic, Panama City, Panama., Lanata C; Instituto de Investigación Nutricional, Lima, Peru., Aranguren E; Cevaxin, The Panama Clinic, Panama City, Panama., Celis CR; Instituto de Investigación Nutricional, La Molina, Peru., Cornejo R; Instituto de Investigación Nutricional, Lima, Peru., DeAntonio R; Cevaxin, The Panama Clinic, Panama City, Panama., Ecker L; Instituto de Investigación Nutricional, Lima, Peru., Garrido D; Cevaxin, The Panama Clinic, Panama City, Panama., Gil AI; Instituto de Investigación Nutricional, La Molina, Peru., Gonzales M; CureVac AG, Tübingen, Germany., Hess-Holtz M; Cevaxin, The Panama Clinic, Panama City, Panama., Leroux-Roels G; Ghent University Hospital, Ghent, Belgium., Junker H; CureVac AG, Frankfurt, Germany., Kays SK; Ghent University Hospital, Ghent, Belgium., Koch SD; CureVac AG, Tübingen, Germany., Lazzaro S; CureVac AG, Tübingen, Germany., Mann P; CureVac AG, Frankfurt, Germany., Quintini G; CureVac AG, Tübingen, Germany., Srivastava B; CureVac AG, Tübingen, Germany., Vahrenhorst D; CureVac AG, Tübingen, Germany., von Eisenhart-Rothe P; CureVac AG, Tübingen, Germany., Wolz OO; CureVac AG, Tübingen, Germany., Oostvogels L; CureVac AG, Frankfurt, Germany.
Publikováno v: Vaccine: X [Vaccine X] 2023 Aug; Vol. 14, pp. 100307. Date of Electronic Publication: 2023 Apr 28.
Zobrazit plný text záznamu
5
Akademický článek
Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study.
Autor: Sáez-Llorens X; Cevaxin, The Panama Clinic, Panama City, Panama., Lanata C; Instituto de Investigación Nutricional, Lima, Peru., Aranguren E; Cevaxin, The Panama Clinic, Panama City, Panama., Celis CR; Cevaxin, The Panama Clinic, Panama City, Panama., Cornejo R; Instituto de Investigación Nutricional, Lima, Peru., DeAntonio R; Cevaxin, The Panama Clinic, Panama City, Panama., Ecker L; Instituto de Investigación Nutricional, Lima, Peru., Garrido D; Cevaxin, The Panama Clinic, Panama City, Panama., Gil AI; Instituto de Investigación Nutricional, La Molina, Peru., Gonzales M; CureVac AG, Tübingen, Germany., Hess-Holtz M; Cevaxin, The Panama Clinic, Panama City, Panama., Leroux-Roels G; Ghent University Hospital, Ghent, Belgium., Junker H; CureVac AG, Frankfurt, Germany., Kays SK; Ghent University Hospital, Ghent, Belgium., Koch SD; CureVac AG, Tübingen, Germany., Lazzaro S; CureVac AG, Tübingen, Germany., Mann P; CureVac AG, Frankfurt, Germany., Quintini G; CureVac AG, Tübingen, Germany., Srivastava B; CureVac AG, Tübingen, Germany., Vahrenhorst D; CureVac AG, Tübingen, Germany., von Eisenhart-Rothe P; CureVac AG, Tübingen, Germany., Wolz OO; CureVac AG, Tübingen, Germany., Oostvogels L; CureVac AG, Frankfurt, Germany.
Publikováno v: Vaccine: X [Vaccine X] 2022 Aug; Vol. 11, pp. 100189. Date of Electronic Publication: 2022 Jul 01.
Zobrazit plný text záznamu
6
Akademický článek
A Third Dose of the COVID-19 Vaccine, CVnCoV, Increased the Neutralizing Activity against the SARS-CoV-2 Wild-Type and Delta Variant.
Autor: Wolz OO; CureVac AG, Friedrich-Miescher-Straße 15, 72076 Tübingen, Germany., Kays SK; CureVac AG, Schumannstr. 27, 60325 Frankfurt, Germany., Junker H; CureVac AG, Schumannstr. 27, 60325 Frankfurt, Germany., Koch SD; CureVac AG, Friedrich-Miescher-Straße 15, 72076 Tübingen, Germany., Mann P; CureVac AG, Schumannstr. 27, 60325 Frankfurt, Germany., Quintini G; CureVac AG, Friedrich-Miescher-Straße 15, 72076 Tübingen, Germany., von Eisenhart-Rothe P; CureVac AG, Friedrich-Miescher-Straße 15, 72076 Tübingen, Germany., Oostvogels L; CureVac AG, Schumannstr. 27, 60325 Frankfurt, Germany.
Publikováno v: Vaccines [Vaccines (Basel)] 2022 Mar 25; Vol. 10 (4). Date of Electronic Publication: 2022 Mar 25.
Zobrazit plný text záznamu
7
Akademický článek
Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trial.
Autor: Kremsner PG; Institute of Tropical Medicine, University Hospital Tübingen, Tübingen, Germany.; German Centre for Infection Research (DZIF), partner site Tübingen, Tübingen, Germany.; Centre de Recherches Medicales de Lambarene, Lambarene, Gabon., Mann P; CureVac AG, Schumannstraße 27, 60325, Frankfurt, Germany. Philipp.Mann@curevac.com., Kroidl A; Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany.; German Centre for Infection Research (DZIF), partner site Munich, Munich, Germany., Leroux-Roels I; Ghent University Hospital, Ghent, Belgium., Schindler C; Hannover Medical School (MHH), Hannover, Germany., Gabor JJ; Institute of Tropical Medicine, University Hospital Tübingen, Tübingen, Germany., Schunk M; Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany.; German Centre for Infection Research (DZIF), partner site Munich, Munich, Germany., Leroux-Roels G; Ghent University Hospital, Ghent, Belgium., Bosch JJ; Hannover Medical School (MHH), Hannover, Germany., Fendel R; Institute of Tropical Medicine, University Hospital Tübingen, Tübingen, Germany.; German Centre for Infection Research (DZIF), partner site Tübingen, Tübingen, Germany., Kreidenweiss A; Institute of Tropical Medicine, University Hospital Tübingen, Tübingen, Germany.; German Centre for Infection Research (DZIF), partner site Tübingen, Tübingen, Germany., Velavan TP; Institute of Tropical Medicine, University Hospital Tübingen, Tübingen, Germany.; Vietnamese-German Center for Medical Research (VG-CARE), Hanoi, Viet Nam., Fotin-Mleczek M; CureVac AG, Tübingen, Germany., Mueller SO; CureVac AG, Schumannstraße 27, 60325, Frankfurt, Germany., Quintini G; CureVac AG, Tübingen, Germany., Schönborn-Kellenberger O; Cogitars, Heidelberg, Germany., Vahrenhorst D; CureVac AG, Tübingen, Germany., Verstraeten T; P95 Epidemiology and Pharmacovigilance, Leuven, Belgium., Alves de Mesquita M; CureVac AG, Schumannstraße 27, 60325, Frankfurt, Germany., Walz L; CureVac AG, Schumannstraße 27, 60325, Frankfurt, Germany., Wolz OO; CureVac AG, Tübingen, Germany., Oostvogels L; CureVac AG, Schumannstraße 27, 60325, Frankfurt, Germany.
Publikováno v: Wiener klinische Wochenschrift [Wien Klin Wochenschr] 2021 Sep; Vol. 133 (17-18), pp. 931-941. Date of Electronic Publication: 2021 Aug 10.
Zobrazit plný text záznamu
8
Akademický článek
Intersectionality and benefit receipt: The interplay between education, gender, age and migration background.
Autor: Slabbekoorn, Jos1 (AUTHOR) j.slabbekoorn@uu.nl, Maas, Ineke1,2 (AUTHOR), Vrooman, J. Cok1,3 (AUTHOR)
Publikováno v: PLoS ONE. 11/14/2024, Vol. 19 Issue 11, p1-24. 24p.
Zobrazit plný text záznamu
9
Akademický článek
Perkembangan Penerapan Teknologi Artificial Intelligence di Indonesia.
Autor: Apriliana, Hanna Kirana1 hannaaprilianaa@gmail.com, Kornarius, Yoke Pribadi1, Caroline, Angela1, Putri Gusti, Triningtyas Elisabeth1, Gunawan, Agus1
Publikováno v: Jurnal Syntax Admiration. Oct2024, Vol. 5 Issue 10, p3864-3874. 11p.
Zobrazit plný text záznamu
10
OECD Skills Outlook 2013: First Results from the Survey of Adult Skills
Autor: Desjardins, R, Thorn, W, Schleicher, A, Quintini, G, Pellizzari, M, Kis, V, Chung, JE
Publikováno v: Desjardins, R; Thorn, W; Schleicher, A; Quintini, G; Pellizzari, M; Kis, V; et al.(2013). OECD Skills Outlook 2013: First Results from the Survey of Adult Skills. UCLA: Retrieved from: http://www.escholarship.org/uc/item/4b75m4tj
The way we live and work has changed profoundly – and so has the set of skills we need to participate fully in and benefit from our hyper-connected societies ... Our new publication series, the OECD Skills Outlook, aims to provide that picture.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::e8cf0b46d9a1fb94b718976718a24108
http://www.escholarship.org/uc/item/4b75m4tj
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje